# Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma

> **NCT00418496** · PHASE1 · COMPLETED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 17 (actual)

## Conditions studied

- Renal Cancer
- Melanoma

## Interventions

- **DRUG:** Aldesleukin
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT00418496
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11-08
- **Primary completion:** 2013-02-28
- **Final completion:** 2013-10
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2017-02-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00418496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00418496, "Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00418496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*